Literature DB >> 19455306

Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.

W L Suarez-Pinzon, G S Cembrowski, A Rabinovitch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19455306     DOI： 10.1007/s00125-009-1390-z

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  10 in total

1.  Role of endogenous hypergastrinemia in regenerating endocrine pancreas after partial pancreatectomy.

Authors:  G Xu; S Sumi; M Koike; K Tanigawa; Y Nio; K Tamura
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

2.  Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

Authors:  James Mu; John Woods; Yun-Ping Zhou; Ranabir Sinha Roy; Zhihua Li; Emanuel Zycband; Yue Feng; Lan Zhu; Cai Li; Andrew D Howard; David E Moller; Nancy A Thornberry; Bei B Zhang
Journal:  Diabetes       Date:  2006-06       Impact factor: 9.461

3.  Randomized prospective trial of the effect of induced hypergastrinemia on the prevention of pancreatic atrophy after pancreatoduodenectomy in humans.

Authors:  Jin-Young Jang; Sun-Whe Kim; Joon-Koo Han; Sang-Jae Park; Youn-Chan Park; Young Joon Ahn; Yong-Hyun Park
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

Review 4.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

Authors:  Daniel J Drucker; Michael A Nauck
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

5.  Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

Authors:  J Andrew Pospisilik; Jennifer Martin; Timothy Doty; Jan A Ehses; Nathalie Pamir; Francis C Lynn; Shalea Piteau; Hans-Ulrich Demuth; Christopher H S McIntosh; Raymond A Pederson
Journal:  Diabetes       Date:  2003-03       Impact factor: 9.461

6.  Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.

Authors:  Tanya Hansotia; Laurie L Baggio; Dominique Delmeire; Simon A Hinke; Yuichiro Yamada; Katsushi Tsukiyama; Yutaka Seino; Jens J Holst; Frans Schuit; D J Drucker
Journal:  Diabetes       Date:  2004-05       Impact factor: 9.461

7.  Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.

Authors:  Norihiko Ogawa; James F List; Joel F Habener; Takashi Maki
Journal:  Diabetes       Date:  2004-07       Impact factor: 9.461

8.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.

Authors:  T J Kieffer; C H McIntosh; R A Pederson
Journal:  Endocrinology       Date:  1995-08       Impact factor: 4.736

9.  Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.

Authors:  Su-Jin Kim; Cuilan Nian; Doris J Doudet; Christopher H S McIntosh
Journal:  Diabetes       Date:  2008-12-10       Impact factor: 9.461

10.  Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.

Authors:  Wilma L Suarez-Pinzon; Robert F Power; Yanhua Yan; Clive Wasserfall; Mark Atkinson; Alex Rabinovitch
Journal:  Diabetes       Date:  2008-10-03       Impact factor: 9.461
  10 in total
  23 in total

1.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

2.  Type 1 diabetes.

Authors:  Paul Burn
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

Review 3.  Combination immunotherapies for type 1 diabetes mellitus.

Authors:  Paolo Pozzilli; Ernesto Maddaloni; Raffaella Buzzetti
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

Review 4.  Thinking bedside at the bench: the NOD mouse model of T1DM.

Authors:  James C Reed; Kevan C Herold
Journal:  Nat Rev Endocrinol       Date:  2015-01-27       Impact factor: 43.330

5.  Regulation of adipocyte differentiation and metabolism by lansoprazole.

Authors:  Ameena Benchamana; Hiroyuki Mori; Ormond A MacDougald; Sunhapas Soodvilai
Journal:  Life Sci       Date:  2019-10-20       Impact factor: 5.037

6.  Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

Authors:  Su-Jin Kim; Cuilan Nian; Christopher H S McIntosh
Journal:  Diabetes       Date:  2010-04-05       Impact factor: 9.461

7.  Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes.

Authors:  T B Bödvarsdóttir; K D Hove; C F Gotfredsen; L Pridal; A Vaag; A E Karlsen; J S Petersen
Journal:  Diabetologia       Date:  2010-06-30       Impact factor: 10.122

8.  Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial.

Authors:  Kurt J Griffin; Paul A Thompson; Michael Gottschalk; Jennifer H Kyllo; Alex Rabinovitch
Journal:  Lancet Diabetes Endocrinol       Date:  2014-07-02       Impact factor: 32.069

9.  Effect of proton pump inhibitors on glycemic control in patients with diabetes.

Authors:  Kohzo Takebayashi; Toshihiko Inukai
Journal:  World J Diabetes       Date:  2015-08-25

Review 10.  Proton pump inhibitors: impact on glucose metabolism.

Authors:  Diana Boj-Carceller
Journal:  Endocrine       Date:  2012-08-12       Impact factor: 3.633
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.